#How do i change phone license key number on disutilities skin
The cost-effectiveness of 2 skin treatment strategies from the perspective of the Japanese healthcare payer was compared. The purpose of this study was to estimate the cost-effectiveness of a preemptive skin treatment for skin toxicity in third-line Pmab therapy for KRAS wild type mCRC compared to a reactive skin treatment from the perspective of the Japanese health insurance system payer. Since health economics is now an important issue to focus on, it is important to consider not only whether statistical differences are clinically significant, but also whether they are clinically significant in terms of health economics. However, the cost-effectiveness of preventive treatment is unclear. It has been reported that preemptive skin treatment is widely used in real world clinical settings. Based on these results, preemptive skin treatment is recommended over reactive skin treatment. In another similar study, Japanese Skin-toxicity Evaluation Protocol with Panitumumab (J-STEPP), involving only Japanese patients, preemptive skin treatments such as sunscreen, skin moisturizers, topical steroids, and minocycline was effective in preventing the development of skin-toxicity in third-line Panitumumab (Pmab) therapy for KRAS wild type mCRC. Skin-toxicity evaluation protocol with panitumumab (STEPP) study showed that preemptive skin treatments such as sunscreens, skin moisturizers, topical steroids, and doxycycline are effective in preventing the development of grade 2 or higher skin-toxicity in the United States. Preemptive skin treatment is an effective strategy for preventing skin-toxicity with anti-EGFR antibodies. Treatment that focuses primarily on preventing serious symptoms of skin-toxicity is important.
Skin-toxicity caused by anti-EGFR antibodies can lead to acne-like dermatitis, paronychia, and dry skin, with deleterious effects on the patient’s quality of life. This drug is a major concern for clinicians because of the skin-toxicity that occurs in almost all patients. Anti-Epidermal Growth Factor Receptor (EGFR) antibodies are widely used in patients for RAS wild type metastatic colorectal cancer (mCRC) from first-line therapy to salvage lines. It has become possible to think that the extension of this survival period is mainly due to the fact that the treatment can be continued, not only the primary treatment, but also the second-line and later treatments due to the emergence of new drugs and molecularly targeted drugs. Those with a median overall survival (OS) of 11 to 12 months in the era of 5-FU single-agent or 5-FU/LV combined administration have recently survived around 30 months. The chemotherapy for unresectable colorectal cancer has made remarkable progress in the last decade. In Japan, colorectal cancer is the second leading cause of death after lung cancer, and more than 50,000 people died of it in 2017. The cost to effectiveness of preemptive treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type mCRC is not high.Ĭolorectal cancer is the fourth most common malignancy in the world and the third leading cause of cancer-related deaths. From PSA, the cost-effectiveness rate of preemptive treatment was 75.0%. The variability of preemptive and reactive treatment costs for skin-toxicity and the disutility of skin-toxicity had a large impact on ICER. Preemptive treatment had incremental effects of 0.0029 QALYs, incremental costs of 5300 JPY (48.6 USD), and incremental cost-effectiveness ratios (ICER) of 1,843,395 JPY (16,912 USD) per QALY. Willingness-to-pay (WTP) threshold of 5 million JPY was used. A 2% annual discount was applied to the expenses and QALYs. The robustness of the model was verified by one-way sensitivity analysis and a probabilistic sensitivity analysis (PSA). The costs were 2020 revisions to the drug prices. The health outcome was quality-adjusted life-years (QALYs). The costs and effectiveness of preemptive treatment was compared with reactive treatment in a 3-year time horizon using a 4-state partitioned survival analysis. The data source was J-STEPP trial, which compared preemptive skin treatment with reactive treatment in third-line panitumumab therapy for KRAS wild type metastatic colorectal cancer in Japan. This study examined the cost-effectiveness of preventive skin care for skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer from the perspective of the Japanese healthcare payer. Results of clinical trials have recommended the efficacy of prophylactic treatment, but the cost-effectiveness is unclear. Clinical management of skin-toxicity associated with the use of anti-Epidermal Growth Factor Receptor (EGFR) antibodies to treat colorectal cancer maintains quality of life of patients with colorectal cancer.
0 kommentar(er)
